MILPITAS, Calif. — LifeScan on Tuesday announced that the U.S. District Court for the Eastern District of New York entered a permanent injunction against Pakistani distributors of counterfeit OneTouch Test Strips and awarded the company damages of $3.3 million.
The judgment against Azam International Trading, Hamid Butt and five related defendants is significant because it is the first time that a federal court awarded the maximum statutory damages under the Lanham Act because of the “real danger to consumers” posed by willful counterfeiting of healthcare products, the company stated.
“This decision emphasizes the importance of pursuing civil enforcement actions as a way of deterring and punishing those who distribute counterfeit healthcare products, particularly those that can cause serious injury or death," stated Roy Albiani, LifeScan director of global brand protection. "We hope that this judgment and permanent injunctions will act as a deterrent to those that would compromise patient health, the security of our supply chain, and the reputation of our brands."
In addition to ongoing legal actions, LifeScan has implemented a global brand protection program to help prevent counterfeit products. The program includes market monitoring to detect counterfeit products; the institution of overt and covert features to readily distinguish genuine from counterfeit products; and distributing genuine products to its customers only through a secure supply chain to ensure the delivery of only authentic LifeScan blood glucose test strips to patients.
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.